EFMH
MDGL icon

E Fund Management (HK)’s Madrigal Pharmaceuticals MDGL Stock Holding History

E Fund Management (HK)’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Buy
47
+14
+42% +$7.17K 0.01% 265
2026
Q1 		$17.3K Buy
+33
New +$15.8K 0.01% 224

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E Fund Management (HK)'s MDGL Position: Q2 2026 in Review

E Fund Management (HK) increased its Madrigal Pharmaceuticals (MDGL) stake by 42% in Q2 2026, buying an estimated $7.17K and bringing the position to 47 shares worth $25.2K. The position accounts for 0.01% of the portfolio, ranked #265.

E Fund Management (HK) first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • E Fund Management (HK) held 47 shares of Madrigal Pharmaceuticals worth $25.2K as of Q2 2026.
  • E Fund Management (HK) bought 14 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $7.17K.
  • Madrigal Pharmaceuticals made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #265 holding.
  • E Fund Management (HK) first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.